UTHR icon

United Therapeutics

371.89 USD
+0.61
0.16%
At close Jan 23, 4:00 PM EST
After hours
371.89
+0.00
0.00%
1 day
0.16%
5 days
2.52%
1 month
2.27%
3 months
5.48%
6 months
10.44%
Year to date
3.24%
1 year
70.76%
5 years
309.25%
10 years
155.95%
 

About: United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Employees: 1,168

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

129% more first-time investments, than exits

New positions opened: 112 | Existing positions closed: 49

10% more funds holding

Funds holding: 559 [Q2] → 615 (+56) [Q3]

4% more capital invested

Capital invested by funds: $14.9B [Q2] → $15.5B (+$588M) [Q3]

6% less funds holding in top 10

Funds holding in top 10: 18 [Q2] → 17 (-1) [Q3]

8.19% less ownership

Funds ownership: 105.74% [Q2] → 97.55% (-8.19%) [Q3]

12% less repeat investments, than reductions

Existing positions increased: 198 | Existing positions reduced: 224

32% less call options, than puts

Call options by funds: $74.3M | Put options by funds: $110M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$302
19%
downside
Avg. target
$424
14%
upside
High target
$600
61%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
UBS
Ashwani Verma
70% 1-year accuracy
14 / 20 met price target
28%upside
$475
Buy
Maintained
8 Jan 2025
Goldman Sachs
Chris Shibutani
55% 1-year accuracy
6 / 11 met price target
19%downside
$302
Neutral
Maintained
1 Nov 2024
Ladenburg Thalmann
Matthew Kaplan
50% 1-year accuracy
2 / 4 met price target
8%downside
$344
Buy
Maintained
31 Oct 2024
Oppenheimer
Hartaj Singh
19% 1-year accuracy
5 / 26 met price target
61%upside
$600
Outperform
Maintained
31 Oct 2024
Argus Research
Jasper Hellweg
14% 1-year accuracy
1 / 7 met price target
8%upside
$400
Buy
Maintained
31 Oct 2024

Financial journalist opinion

Based on 8 articles about UTHR published over the past 30 days

Neutral
Business Wire
2 days ago
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its commercial and development portfolio in pulmonary hypertension (PH) will be presented at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29 through February 1, 2025 in Rio de Janeiro. In addition, professionals from United Therapeutics will participate in two speak.
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
Positive
Zacks Investment Research
1 week ago
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Negative
Zacks Investment Research
2 weeks ago
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?
Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?
Positive
Zacks Investment Research
2 weeks ago
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Positive
Zacks Investment Research
2 weeks ago
UTHR vs. STVN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
UTHR vs. STVN: Which Stock Is the Better Value Option?
Neutral
Business Wire
2 weeks ago
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company's business during a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 13, 2025, from 2:15 p.m. to 2:55 p.m., Pacific Standard Time,.
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
Seeking Alpha
3 weeks ago
The Zen Ten - My Top Picks For 2025
I've been publishing the Zen Ten list since 2008, consistently beating the market by an average of 9.1% per year since 2000. My methodology involves a rigorous three-step screening process using Zacks Investment Research, LSEG StarMine, and StockRover, narrowing 8,000 stocks to just 10. The screening process focuses on earnings growth, value, quality, financial stability, profitability, sustainability, and margin of safety, ensuring a diversified and robust selection.
The Zen Ten - My Top Picks For 2025
Positive
Zacks Investment Research
4 weeks ago
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Positive
Zacks Investment Research
1 month ago
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Neutral
Business Wire
1 month ago
United Therapeutics Announces Successful World's First UKidney Transplant
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)---- $UTHR #biotech--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world's first transplant of a UKidney, which it produced, into a living person on November 25, 2024. The transplant is the fourth xenotransplant using United Therapeutics' xeno organs into living humans, following two successful UHeart transplants at the University of Maryland Medicine in 2022 and 2023 and a successful UThymoKidney.
United Therapeutics Announces Successful World's First UKidney Transplant
Charts implemented using Lightweight Charts™